Human Recombinant Fractalkine (CX3CL1)

Fractalkine

Human Recombinant Fractalkine (CX3CL1)

Fractalkine

From: 278 USD
Catalog #
78051_C
Fractalkine

Overview

Fractalkine (CX3CL1) is a unique chemokine belonging to the CX3C family, and is characterized by a C-X3-C cysteine motif within the chemokine domain, near the amino terminus of the protein (Bazan et al.). The chemokine domain is connected to an extended mucin-like stalk, followed by a transmembrane region, and a C-terminal intracellular domain (Imai et al.; Jones et al.). The protein signals through interaction with a single receptor, CX3CR1, expressed on monocytes, natural killer cells, T cells, microglia, and smooth muscle cells. Fractalkine is upregulated in endothelial cells by inflammatory signals and is synthesized as a membrane-bound molecule that mediates cell migration and adhesion (White & Greaves). Cleavage at the base of the stalk by metalloproteinases generates a soluble chemokine, which functions as a potent chemoattractant of target cells (Garton et al.; Apostolakis & Spandidos). Fractalkine has been implicated in pathology of inflammatory diseases, such as atherosclerosis and other vascular diseases, and has anti-apoptotic functions (White & Greaves).
Subtype
Cytokines
Alternative Names
C3Xkine, Chemokine (C-X3-C motif) ligand 1, FKN, Neurotactin, NTN, NTT, SCYD1, Small inducible cytokine subfamily D member 1
Cell Type
Dendritic Cells, Endothelial Cells, Macrophages, Monocytes, NK Cells, T Cells
Species
Human
Area of Interest
Endothelial Cell Biology, Immunology
Molecular Weight
50 - 75 kDa
Purity
≥ 95%

Data Figures

(A) The biological activity of Human Recombinant Fractalkine (CX3CL1) was tested by its ability to mobilize Ca2+ in CHO-K1/Gα15/hCX3CR1 (human Gα15 and human CX3CR1 stably expressed in CHO-K1 cells) cells. Ca2+ mobilization was measured using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which Ca2+ mobilization is at 50% of maximum. The EC50 in the example above is less than 1.5 μg/mL. (B) 2 μg of Human Recombinant Fractalkine (CX3CL1) was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant Fractalkine (CX3CL1) has a predicted molecular mass of 50 - 75 kDa.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
78051.1
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
78051.1
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.